Columbia Care Inc. CCHW CCHW CCHWF recently reported its financial and operating results for the second quarter ended June 30, 2021, revealing a 232% year-over-year and 19% sequential revenue pop to $109.7 million.
The Analyst
Cantor Fitzgerald’s Pablo Zuanic upgraded the ‘Neutral’ rating on the stock to ‘Overweight’ and raised the price target from $5.30 to $5.50.
The Thesis
While considering the sectoral derating, the analyst upgraded the rating on Columbia Care based on increased estimates.
“As we have written in other notes, we think the current sector malaise is overdone, especially in what relates to the US group (AdvisorShares Trust AdvisorShares Pure US Cannabis ETF MSOS is down 20% over the last 3- month period versus +7% for SPDR S&P 500 (ARCA: SPY) ). But this also provides an attractive entry point into some of these stocks, in our view,” Zuanic pointed out.
With Columbia Care being down 30% over the same period despite its reaffirmed guidance for the full year, there is a potential upside from several eastern states where it has vertically integrated operations – New Jersey, New York, Virginia, Pennsylvania, Maryland, the analyst explained.
In the case of New Jersey, the potential upside can come as quickly as February.
“We think the FactSet consensus CY22 sales estimate does not properly reflect the New Jersey ramp, various cultivation expansion plans, or the Medicine Man deal in Colorado (we are 14% above consensus in sales, but in-line on EBITDA, assuming margins 4pt below consensus).”
With the targeted share price of $5.50, the analyst projected a potential upside of around 40%.
“We also think the company EV of $1.92Bn makes it more reachable for those looking for partnerships or contingent buyouts. Like Trulieve (OTCQX: TCNNF) Columbia Care trades 5-6pts below the MSO group stand outs Curealeaf (OTCQX: CURLF) and Green Thumb Industries (OTCQX: GTBIF)," Zuanic concluded.
Price Action
Columbia Care’s shares were trading 1.72% higher at $4.08 per share at the time of writing Friday morning.
Photo: Courtesy of herbadea Berlin on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.